Retatrutide vs Tirzepatide
Quick Answer
Tirzepatide is a dual incretin receptor agonist targeting GLP-1R and GIPR. Retatrutide adds a third target, the glucagon receptor (GCGR), making it a triple agonist. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity; retatrutide is investigational and has no FDA approval for any indication. The glucagon receptor arm is the entire pharmacological difference, and it is what drives retatrutide's greater energy-expenditure and lipolysis signal in published trial data. Both are supplied at ≥99% HPLC-verified purity for in-vitro laboratory research only.
Retatrutide vs Tirzepatide: At a Glance
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1R + GIPR + GCGR (triple) | GLP-1R + GIPR (dual) |
| Lilly development code | LY3437943 | LY3298176 |
| CAS number | 2381089-83-2 | 2023788-19-2 |
| Molecular weight | ~4,731 Da | ~4,813.5 Da |
| Molecular formula | Not publicly disclosed by Eli Lilly | C225H348N48O68 |
| Amino acid count | 39 | 39 |
| Lipidation | Fatty-acylated for albumin binding | C20 fatty diacid at Lys20 |
| FDA status | Investigational — not approved for any indication | Approved: Mounjaro (T2DM), Zepbound (obesity) |
| Clinical trial stage | Phase 3 (TRIUMPH programme) | Phase 3 complete (SURMOUNT, SURPASS) |
| Added receptor vs the other | GCGR — thermogenesis and hepatic lipolysis | None — tirzepatide is the subset |
| Purity (Peptide.Express) | ≥99% HPLC verified | ≥99% HPLC verified |
How Retatrutide and Tirzepatide Differ in Research
These two compounds share a backbone architecture — both are 39-amino-acid fatty-acylated incretin analogs from the same developer — and differ in one respect that matters: retatrutide engages the glucagon receptor and tirzepatide does not.
That third receptor changes the metabolic direction of the molecule rather than simply amplifying it. GLP-1R and GIPR activation both act to lower glucose. GCGR activation raises hepatic glucose output, which sounds contradictory until you account for what else it does: it increases energy expenditure through thermogenesis and promotes lipolysis. The net glycaemic effect stays favourable because the GLP-1R arm counterbalances the glucagon arm, while the thermogenic and lipolytic effects add on top.
The regulatory gap between them is as important as the pharmacological one, and it is where most online comparisons are careless. Tirzepatide has completed Phase 3 and carries two FDA approvals. Retatrutide has published Phase 2 data and is in Phase 3. Phase 2 results are generated in smaller cohorts over shorter durations with different selection criteria, and the history of drug development is full of Phase 2 effect sizes that did not survive Phase 3. The Jastreboff 2023 NEJM retatrutide figures are real, and they are not yet confirmed.
One further honest gap: Eli Lilly has not publicly released retatrutide's primary structure. Any source quoting a full amino-acid sequence for it is not working from a disclosed reference. Peptide.Express reports the molecular weight from the canonical entity record and leaves the formula blank rather than filling it with an approximation.
Frequently Asked Questions
What is the difference between retatrutide and tirzepatide?
The glucagon receptor. Tirzepatide activates GLP-1R and GIPR. Retatrutide activates those two plus GCGR, which adds thermogenesis and hepatic lipolysis to the pharmacology. Structurally both are 39-amino-acid fatty-acylated peptides of similar molecular weight.
Is retatrutide FDA approved?
No. Retatrutide is investigational, currently in Phase 3 trials, and is not approved by the FDA for any indication.
Is tirzepatide FDA approved?
Yes — as Mounjaro for type 2 diabetes and as Zepbound for obesity. That approval applies to the pharmaceutical product, not to research-market material.
Does retatrutide produce more weight loss than tirzepatide?
Published Phase 2 retatrutide data reported a larger magnitude at the highest dose than tirzepatide's Phase 3 figures at comparable timepoints. Those are not equivalent evidence standards and the comparison is not a head-to-head trial. No direct retatrutide-versus-tirzepatide study has been published.
What does triple agonist mean?
That a single molecule activates three separate receptors — in retatrutide's case the GLP-1, GIP and glucagon receptors. Dual agonism, as in tirzepatide, means two.
Why would activating the glucagon receptor be useful when glucagon raises blood sugar?
Because GCGR activation also drives thermogenesis and lipolysis, and the simultaneous GLP-1R activation counterbalances the glycaemic effect. The combination is what makes the third receptor additive rather than counterproductive.
What is retatrutide's amino acid sequence?
Not publicly disclosed. Eli Lilly has not released the primary structure. Sources presenting a complete sequence are not citing a disclosed reference.
Are both available at the same purity?
Yes. Both are verified at ≥99% purity by reverse-phase HPLC with LC-MS/MS molecular identity confirmation, and ship with a batch-specific Certificate of Analysis. All material is for in-vitro laboratory research use only.